US Patent

US7449458 — Prodrugs of 2,4-pyrimidinediamine compounds and their uses

Composition of Matter · Assigned to Rigel Pharmaceuticals Inc · Expires 2031-09-04 · 5y remaining

Vulnerability score 10/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects prodrugs of biologically active 2,4-pyrimidinediamine compounds, including their synthesis and uses in treating autoimmune diseases.

USPTO Abstract

The present disclosure provides prodrugs of biologically active 2,4-pyrimidinediamine compounds of structural formula shown below, compositions comprising these compounds, intermediates and methods for synthesizing these compounds, and methods for using these compounds in a variety of applications including treatment of autoimmune diseases.

Drugs covered by this patent

Patent Metadata

Patent number
US7449458
Jurisdiction
US
Classification
Composition of Matter
Expires
2031-09-04
Drug substance claim
Yes
Drug product claim
No
Assignee
Rigel Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.